NCT07565870
Methadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY)
Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatmentAlexandre P. JoostenInvestigator-initiated
~400 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Intravenous MethadoneShort-acting Opioids Intraoperative analgesia
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quality of Recovery (QoR-15) score on postoperative day 1
Measured over Postoperative Day 1 (24 hours after surgery)
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Joseph Szokol, MD PhD · STUDY_DIRECTOR · University of California, Los Angeles
- EVAN KARASCH, MD PhD · STUDY_DIRECTOR · DUKE
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age ≥18 years
Elective intermediate-risk noncardiac surgery under general anesthesia
ASA physical status I-III
Expected hospital stay ≥24 hours
Ability to provide informed consent
Exclusion
Severe hepatic dysfunction (Child-Pugh C)
Severe renal impairment (eGFR \<30 mL/min/1.73 m²)
Known allergy to methadone or opioids
Pregnancy or breastfeeding
Chronic opioid use or opioid use disorder
Planned use of epidural or regional analgesia
Inability to complete study assessments
What this trial measures
- Quality of Recovery (QoR-15) score on postoperative day 1Postoperative Day 1 (24 hours after surgery)
Quality of recovery assessed using the validated 15-item QoR-15 questionnaire. Scores range from 0 to 150, with higher scores indicating better recovery.